Tuesday, September 20, 2016

Theravance Biopharma - Chart of the Day

Theravance Biopharma (TBPH) is the Barchart Chart of the Day.  The biopharmaceutical company has a Trend Spotter buy signal, a Weighted Alpha of 200.40+ and gained 159.76% in the last year.

The Chart of the Day belongs to Theravance Biopharma (TBPH).  I found the biopharmaceutical stock by using Barchart to sort the Russell 3000 Index stocks first for the highest Weighted Alpha, then again for technical buy signals of 80% or more.  Since the Trend spotter signaled a buy on 7/27 the sock gained 45.37%.

Theravance Biopharma, Inc. is a biopharmaceutical company. It is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including bacterial infections, central nervous system (CNS)/pain, respiratory disease, and gastrointestinal (GI) motility dysfunction. Theravance Biopharma, Inc. is based in George Town, Cayman Islands.

The status of Barchart's Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com web site when you read this report.

Barchart technical indicators:
  • 100% technical buy signals
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 15 new highs and up 25.72% in the last month
  • Relative Strength Index 76.64%
  • Technical support level at 32.56
  • Recently traded at 35.10 with a 50 day moving average of 27.06

Fundamental factors:
  • Market Cap $1.66 billion
  • Revenue expected to grow 11.00% this year but decline by 5.60% next year
  • Earnings estimated to increase 24.50% this year, an additional .70% next year, and continue to compound at an annual rate of 376.60% for the next 5 years
  • Wall Street analysts issued 3 strong buy, 1 hold and 1 sell recommendation on the stock

No comments:

Post a Comment